Titre : Tumeurs de l'abdomen

Tumeurs de l'abdomen : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs de l'abdomen : Questions médicales les plus fréquentes", "headline": "Tumeurs de l'abdomen : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs de l'abdomen : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-09", "dateModified": "2025-04-04", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs de l'abdomen" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs par siège", "url": "https://questionsmedicales.fr/mesh/D009371", "about": { "@type": "MedicalCondition", "name": "Tumeurs par siège", "code": { "@type": "MedicalCode", "code": "D009371", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.588" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tumeurs du rétropéritoine", "alternateName": "Retroperitoneal Neoplasms", "url": "https://questionsmedicales.fr/mesh/D012186", "about": { "@type": "MedicalCondition", "name": "Tumeurs du rétropéritoine", "code": { "@type": "MedicalCode", "code": "D012186", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.588.033.731" } } }, { "@type": "MedicalWebPage", "name": "Nodule de Soeur Marie-Joseph", "alternateName": "Sister Mary Joseph's Nodule", "url": "https://questionsmedicales.fr/mesh/D058288", "about": { "@type": "MedicalCondition", "name": "Nodule de Soeur Marie-Joseph", "code": { "@type": "MedicalCode", "code": "D058288", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.588.033.740" } } } ], "about": { "@type": "MedicalCondition", "name": "Tumeurs de l'abdomen", "alternateName": "Abdominal Neoplasms", "code": { "@type": "MedicalCode", "code": "D000008", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Robert Stoehr", "url": "https://questionsmedicales.fr/author/Robert%20Stoehr", "affiliation": { "@type": "Organization", "name": "Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany." } }, { "@type": "Person", "name": "Abbas Agaimy", "url": "https://questionsmedicales.fr/author/Abbas%20Agaimy", "affiliation": { "@type": "Organization", "name": "Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany. abbas.agaimy@uk-erlangen.de." } }, { "@type": "Person", "name": "Naseema Gangat", "url": "https://questionsmedicales.fr/author/Naseema%20Gangat", "affiliation": { "@type": "Organization", "name": "Mayo Clinic, Rochester, MN, USA." } }, { "@type": "Person", "name": "Paul H Sugarbaker", "url": "https://questionsmedicales.fr/author/Paul%20H%20Sugarbaker", "affiliation": { "@type": "Organization", "name": "Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, District of Columbia, USA." } }, { "@type": "Person", "name": "David Chang", "url": "https://questionsmedicales.fr/author/David%20Chang", "affiliation": { "@type": "Organization", "name": "Westat, Rockville, Maryland, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.", "datePublished": "2023-07-27", "url": "https://questionsmedicales.fr/article/37498324", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00262-023-03501-8" } }, { "@type": "ScholarlyArticle", "name": "C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.", "datePublished": "2024-06-04", "url": "https://questionsmedicales.fr/article/38893521", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/molecules29112646" } }, { "@type": "ScholarlyArticle", "name": "The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.", "datePublished": "2023-03-25", "url": "https://questionsmedicales.fr/article/36966236", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41416-023-02218-w" } }, { "@type": "ScholarlyArticle", "name": "Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.", "datePublished": "2023-03-06", "url": "https://questionsmedicales.fr/article/36889184", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.molimm.2023.02.007" } }, { "@type": "ScholarlyArticle", "name": "Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.", "datePublished": "2023-02-27", "url": "https://questionsmedicales.fr/article/36848319", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cncr.34683" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tumeurs", "item": "https://questionsmedicales.fr/mesh/D009369" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs par siège", "item": "https://questionsmedicales.fr/mesh/D009371" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs de l'abdomen", "item": "https://questionsmedicales.fr/mesh/D000008" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs de l'abdomen - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs de l'abdomen", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs de l'abdomen", "description": "Comment diagnostiquer une tumeur abdominale ?\nQuels tests sanguins sont utiles ?\nQuels symptômes indiquent une tumeur abdominale ?\nQuelle imagerie est la plus précise ?\nQuand faire une échographie abdominale ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs de l'abdomen", "description": "Quels sont les symptômes courants des tumeurs abdominales ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes sans tumeur visible ?\nLes tumeurs abdominales causent-elles des vomissements ?\nComment la fatigue est-elle liée aux tumeurs ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs de l'abdomen", "description": "Peut-on prévenir les tumeurs abdominales ?\nLe tabagisme augmente-t-il le risque ?\nL'alcool est-il un facteur de risque ?\nLes infections peuvent-elles causer des tumeurs ?\nLe surpoids est-il un risque ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs de l'abdomen", "description": "Quels sont les traitements des tumeurs abdominales ?\nQuand est la chirurgie nécessaire ?\nLa chimiothérapie est-elle efficace ?\nQuels effets secondaires des traitements ?\nLa radiothérapie est-elle utilisée ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs de l'abdomen", "description": "Quelles complications peuvent survenir ?\nLes tumeurs peuvent-elles causer des douleurs chroniques ?\nComment les tumeurs affectent-elles la digestion ?\nLes tumeurs abdominales peuvent-elles causer des infections ?\nQuelles sont les conséquences d'une métastase ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs de l'abdomen", "description": "Quels sont les principaux facteurs de risque ?\nLes antécédents médicaux influencent-ils le risque ?\nL'exposition à des produits chimiques est-elle un risque ?\nLe stress a-t-il un impact sur le risque ?\nLes maladies génétiques augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une tumeur abdominale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par imagerie (IRM, scanner) et biopsie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utiles ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs tumoraux comme l'AFP et le CA 19-9 peuvent aider au diagnostic." } }, { "@type": "Question", "name": "Quels symptômes indiquent une tumeur abdominale ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Douleurs abdominales, perte de poids, nausées et changements d'appétit." } }, { "@type": "Question", "name": "Quelle imagerie est la plus précise ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM est souvent plus précise pour visualiser les tissus mous." } }, { "@type": "Question", "name": "Quand faire une échographie abdominale ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie est utile pour évaluer des masses abdominales suspectes." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des tumeurs abdominales ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleurs, ballonnements, nausées et perte d'appétit." } }, { "@type": "Question", "name": "La jaunisse est-elle un symptôme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la jaunisse peut indiquer une tumeur au foie ou des voies biliaires." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans tumeur visible ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes peuvent apparaître même sans tumeur détectable." } }, { "@type": "Question", "name": "Les tumeurs abdominales causent-elles des vomissements ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vomissements peuvent survenir en raison de l'obstruction intestinale." } }, { "@type": "Question", "name": "Comment la fatigue est-elle liée aux tumeurs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La fatigue peut résulter de la maladie, des traitements ou de l'anémie." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs abdominales ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures comme une alimentation saine et l'exercice peuvent réduire le risque." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque pour plusieurs types de tumeurs abdominales." } }, { "@type": "Question", "name": "L'alcool est-il un facteur de risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une consommation excessive d'alcool peut augmenter le risque de tumeurs hépatiques." } }, { "@type": "Question", "name": "Les infections peuvent-elles causer des tumeurs ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme l'hépatite B, peuvent augmenter le risque de cancer du foie." } }, { "@type": "Question", "name": "Le surpoids est-il un risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité est associée à un risque accru de plusieurs tumeurs abdominales." } }, { "@type": "Question", "name": "Quels sont les traitements des tumeurs abdominales ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent chirurgie, chimiothérapie et radiothérapie." } }, { "@type": "Question", "name": "Quand est la chirurgie nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est souvent nécessaire pour retirer la tumeur et les tissus environnants." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut réduire la taille des tumeurs et prévenir les récidives." } }, { "@type": "Question", "name": "Quels effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, fatigue, et perte de cheveux." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est utilisée pour traiter certaines tumeurs abdominales localisées." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la métastase, l'obstruction intestinale et l'hémorragie." } }, { "@type": "Question", "name": "Les tumeurs peuvent-elles causer des douleurs chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tumeurs peuvent provoquer des douleurs chroniques en raison de leur taille ou de leur emplacement." } }, { "@type": "Question", "name": "Comment les tumeurs affectent-elles la digestion ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer des obstructions, entraînant des problèmes digestifs." } }, { "@type": "Question", "name": "Les tumeurs abdominales peuvent-elles causer des infections ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tumeurs peuvent affaiblir le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une métastase ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases peuvent affecter d'autres organes, compliquant le traitement et le pronostic." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le tabagisme, l'alcool et des antécédents familiaux." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies comme la colite peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques est-elle un risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de cancer abdominal." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer la santé globale, mais son lien direct est moins clair." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies génétiques comme le syndrome de Lynch augmentent le risque." } } ] } ] }

Sources (10000 au total)

Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.

Disruptions in lipid metabolism and amino acids have been increasingly linked to resistance to immunotherapy. However, the underlying mechanisms by which dysregulated serum lipid metabolism and amino ... To elucidate the potential associations between lipid metabolism, amino acids, and PD-1/PD-L1, we employed the powerful Mendelian randomization (MR) method, leveraging large-scale genome-wide associat... In the present MR study, we identified a noteworthy negative association between alanine and PD-1 expression, implicating a regulatory role for alanine metabolism in modulating the immune response to ... These findings provided new insights into the role of lipid metabolism as well as amino acids in regulating PD-1/PD-L1, suggesting that strategies targeting lipid and amino acid metabolisms may have t...

C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.

The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positivel...

The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.

Tumour-infiltrating lymphocytes (TILs) represent a robust biological prognostic biomarker in triple-negative breast cancer (TNBC); however, the contribution of different subsets of immune cells is unc... In total, 259 patients with Stage I-III TNBC were reviewed. The density of sTILs along with the presence of total (t), stromal (s), and intratumoral (i) CD8... All immune markers were positively correlated with each other (P < 0.05). In the multivariate analysis, sTILs (P = 0.046), tCD8... In addition to sTILs, inclusion of tCD8...

Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.

Activation of PD-1 by anchoring it to Antigen Receptor (AR) components or associated co-receptors represents an attractive approach to treat autoimmune conditions. In this study, we provide evidence t...

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.

The availability of agents targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has transformed treatment of advanced and/or metastatic non-small ce...

EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR IN ENDOMETRIAL CANCER PATIENTS WITH METABOLIC DISORDERS.

To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders.... Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against CD279 were used to detect PD-1 on the CD4+ and CD8+ T cells. Antibodies against CD14 and CD274 were us... In patients with severe metabolic disorders, the expression of PD-1 on CD8+ and CD4+ lymphocytes and the expression of the corresponding PD-L1 on CD14+ cells before treatment and after radiation thera... Theincreased expression of PD-1 and PD-L1 receptors by immunocompetent cells can be considered a new prognostic marker in endometrial cancer patients with morbid obesity....

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China.

Programmed death receptor 1 (PD-1) inhibition has shown durable response and mild adverse events (AEs) in adult malignancies. However, data on the clinical activity of PD-1 inhibition in pediatric pat... We conducted a real-world, multi-institutional, retrospective analysis of pediatric malignancies treated with PD-1 inhibitor-based regimens. The primary endpoints were objective response rate (ORR) an... A total of 93 and 109 patients were evaluated for efficacy and safety, respectively. For all efficacy-evaluable patients, PD-1 inhibitor monotherapy, combined chemotherapy, combined histone deacetylas... This largest retrospective analysis demonstrate that PD-1 inhibitor-based regimens are potentially effective and tolerable in pediatric malignancies. Our findings provide references for future clinica...

Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer.

Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation t...